Several medical research institutions are reconsidering the use of five stem cell lines that are approved for federal-funded research by the National Institutes of Health, citing recently discovered problems with the consent forms signed by the patients at fertility clinics who donated their extra embryos to medical research. Now, ethics oversight committees at universities across the United States are questioning which lines should be permissible for research [Nature News].
Stanford and San Francisco-based [California Institute for Regenerative Medicine] — the $3 billion state agency created when California voters approved the sale of bonds to fund embryonic stem cell research — along with Johns Hopkins University have stopped or may stop research on five of the 21 lines that President Bush in August 2001 deemed acceptable for federal funding [San Jose Business Journal]. Researchers had already chafed at the narrow range of genetic diversity available from the 21 lines; this new development is likely to further limit their research options.
